The Axin-related protein, Axin2, presumably plays an important role in the regulation of the stability of beta-catenin in the Wnt signaling pathway, like its rodent homologs, mouse conductin/rat axil. In mouse, conductin organizes a multiprotein complex of APC (adenomatous polyposis of the colon), beta-catenin, glycogen synthase kinase 3-beta, and conductin, which leads to the degradation of beta-catenin.
The deregulation of beta-catenin is an important event in the genesis of a number of malignancies. The AXIN2 gene has been mapped to 17q23-q24, a region that shows frequent loss of heterozygosity in breast cancer, neuroblastoma, and other tumors. Mutations in this gene have been associated with colorectal cancer with defective mismatch repair.
The most critical events of teeth, lip and palate formation occur almost concurrently. Hypodontia, defined as the congenital lack of one or more permanent teeth, is the most common dental abnormality found in humans and affects approximately 20% of the population worldwide. AXIS inhibition protein 2 (AXIN2) gene polymorphic variants may be associated with both hypodontia and oligodontia (characterized by the lack of six or more permanent teeth). Mutations of this gene have been found in individuals with colorectal carcinomas and liver tumors.
An AXIN2 mutation (1966C>T) detected in a Finnish family was associated with both tooth agenesis and colon neoplasia. In essence, the mutation seems to disrupt tooth development early in life and later contributes to the emergence of polyps and eventually colon cancer, an observation that suggests that the lack of permanent teeth may be an indicator of colon cancer susceptibility. Dentists may at the very least need to remain aware of the possible association, to be able to detect such cases of tooth agenesis and forward the patient to more complete genetic diagnostic examinations. This is a simple example of how molecular genetic discoveries today interact with traditional disciplines (Longtin, 2004).
^Mai M, Qian C, Yokomizo A, Smith DI, Liu W (May 1999). "Cloning of the human homolog of conductin (AXIN2), a gene mapping to chromosome 17q23-q24". Genomics. 55 (3): 341–4. doi:10.1006/geno.1998.5650. PMID10049590.
^Mostowska A, Biedziak B, Jagodzinski PP (2006). "Axis inhibition protein 2 (AXIN2) polymorphisms may be a risk factor for selective tooth agenesis". J. Hum. Genet. 51 (3): 262–6. doi:10.1007/s10038-005-0353-6. PMID16432638.
Bonaldo MF, Lennon G, Soares MB (1997). "Normalization and subtraction: two approaches to facilitate gene discovery". Genome Res. 6 (9): 791–806. doi:10.1101/gr.6.9.791. PMID8889548.
Liu W, Dong X, Mai M, Seelan RS, Taniguchi K, Krishnadath KK, Halling KC, Cunningham JM, Boardman LA, Qian C, Christensen E, Schmidt SS, Roche PC, Smith DI, Thibodeau SN (2000). "Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling". Nat. Genet. 26 (2): 146–7. doi:10.1038/79859. PMID11017067.
Dong X, Seelan RS, Qian C, Mai M, Liu W (2001). "Genomic structure, chromosome mapping and expression analysis of the human AXIN2 gene". Cytogenet. Cell Genet. 93 (1–2): 26–8. doi:10.1159/000056942. PMID11474173.
Leung JY, Kolligs FT, Wu R, Zhai Y, Kuick R, Hanash S, Cho KR, Fearon ER (2002). "Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling". J. Biol. Chem. 277 (24): 21657–65. doi:10.1074/jbc.M200139200. PMID11940574.
Kouzmenko AP, Takeyama K, Ito S, Furutani T, Sawatsubashi S, Maki A, Suzuki E, Kawasaki Y, Akiyama T, Tabata T, Kato S (2004). "Wnt/beta-catenin and estrogen signaling converge in vivo". J. Biol. Chem. 279 (39): 40255–8. doi:10.1074/jbc.C400331200. PMID15304487.
Hughes TA, Brady HJ (2005). "Expression of axin2 is regulated by the alternative 5'-untranslated regions of its mRNA". J. Biol. Chem. 280 (9): 8581–8. doi:10.1074/jbc.M410806200. PMID15611123.
Hughes TA, Brady HJ (2005). "E2F1 up-regulates the expression of the tumour suppressor axin2 both by activation of transcription and by mRNA stabilisation". Biochem. Biophys. Res. Commun. 329 (4): 1267–74. doi:10.1016/j.bbrc.2005.02.102. PMID15766563.
Koinuma K, Yamashita Y, Liu W, Hatanaka H, Kurashina K, Wada T, Takada S, Kaneda R, Choi YL, Fujiwara SI, Miyakura Y, Nagai H, Mano H (2006). "Epigenetic silencing of AXIN2 in colorectal carcinoma with microsatellite instability". Oncogene. 25 (1): 139–46. doi:10.1038/sj.onc.1209009. PMID16247484.
Lejeune S, Guillemot F, Triboulet JP, Cattan S, Mouton C, Porchet N, Manouvrier S, Buisine MP (2006). "Low frequency of AXIN2 mutations and high frequency of MUTYH mutations in patients with multiple polyposis". Hum. Mutat. 27 (10): 1064. doi:10.1002/humu.9460. PMID16941501.